AstraZeneca's Atacand Adds ACE Inhibitor Combo Claim For Heart Failure

Angiotensin receptor blocker is the first in its class to gain the indication. FDA's approval is in line with the Cardio-Renal Advisory Committee's unanimous recommendation in February.